NUMMUS ESG REPORT

Cliente: PHARUS SICAV

Portafoglio: Medical Innovation

Data report: 31 March 2025






Sustainable Score Analysis


The sustainable score analysis is carried out on the entire portfolio

Portfolio Scores	ESG Rating	ESG Quality Score 7.58	Environmental (Weight - 7.3%) 9.05	Social (Weight - 55.5%)	Governance (Weight - 37.2%) 7.66	
	ESG Rating		Environmental	Social	Governance	
Benchmark Scores	Loo nating	ESG Quality Score	(Weight - 7.3%)	(Weight - 55.5%)	(Weight - 37.2%)	

ESG Rating Distribution



ESG Comparison - Universe vs Portfolio









31-March-2025

ESG Rating Momentum



ESG Rating Leaders & Laggards



ESG Quality Score measures the ability of underlying holdings to manage key medium to long-term risks and opportunities arising from environmental, social, and governance factors. It is measured on a scale of 0 to 10 (worst to best).

ESG Ratings Distribution represents the percentage of a portfolio's market value coming from holdings classified as ESG Ratings Leaders (A+ and A), Average (B+ and B), and Laggards (C+ and C).

ESG Ratings Momentum represents the percentage of a portfolio's market value coming from holdings that have had an ESG Ratings upgrade, and those with a downgrade, since their previous ESG Rating assessment.

ESG Comparison Chart: ESG Universe represents the unweighted set of all issuers in the portfolio and in the benchmark

The ESG Quality Score (Max score of 10; Min score of 0) incorporates the following:

- 1. the underlying holdings' Weighted ESG Score (which is a portfolio weighted average of an issuers' ESG Rating Industry-Adjusted Scores or Government Adjusted ESG Score)
- 2. ESG Momentum, including the portfolio's exposure to holdings with an improving ESG rating momentum (positive) and the portfolio's exposure holding with a worsening ESG rating momentum (negative).
- 3. Exposure to ESG Tail Risk, specifically holdings with C+ and C (Laggards) ESG Ratings.

Expressed formulaically: ESG Quality Score = Weighted ESG Score * (1 - % Exposure to Laggards - % Exposure to Negative Momentum + % Exposure to Positive Momentum)

Sustainable Score Analysis The sustainable score analysis is carried out on the entire portfolio

Sector Breakdown									_
	ESG Score	Portfolio Weight	A+	А	B+	В	C+	С	Not Rated
Corporates									
Consumer Discretionary Consumer Staples Energy Financials Health Care Industrials Information Technology Materials Real Estate Communication Services Utilities No sector	7.1	100.00%	11.0%	36.2%	47.6%	4.9%	0.3%	0.0%	0.0%
Government Related									
Agencies Local Authorities Sovereigns Supranationals									

LOWEST ESG RATED POSITIONS IN PORTFOLIO						
ISSUER	PORTFOLIO WEIGHT	SECTOR	ESG RATING			
GRAIL INC	0.29%	Health Care	C+			
OMNIAB INC	0.00%	Health Care	C+			
THERMO FISHER SCIENTIFIC INCORPORATED	2.82%	Health Care	В			
IONIS PHARMACEUTICALS, INC.	1.58%	Health Care	В			
<no b+="" below="" company="" further="" rating=""></no>						

HIGHEST ESG RATED POSITIONS IN PORTFOLIO						
ISSUER	PORTFOLIO WEIGHT	SECTOR	ESG RATING			
NOVO NORDISK A/S	3.08%	Health Care	A+			
GILEAD SCIENCES, INC.	2.29%	Health Care	A+			
ELEVANCE HEALTH, INC.	1.97%	Health Care	A+			
EDWARDS LIFESCIENCES CORPORATION	1.64%	Health Care	A+			
WATERS CORPORATION	0.82%	Health Care	A+			
GSK PLC	4.27%	Health Care	A			
MOLINA HEALTHCARE, INC.	3.19%	Health Care	A			
HUMANA INC.	3.00%	Health Care	A			
THE CIGNA GROUP	2.97%	Health Care	A			
CENTENE CORPORATION	2.96%	Health Care	A			

HIGHEST WEIGHTED POSITIONS IN PORTFOLIO						
ISSUER	PORTFOLIO WEIGHT	ESG RATING	Momentum	COUNTRY	SECTOR	SUB SECTOR
GSK PLC	4.27%	Α	Neutral	United Kingdom	Health Care	Pharmaceuticals
AMGEN INC.	3.95%	B+	Negative	United States of America	Health Care	Biotechnology
MERCK & CO., INC.	3.93%	B+	Neutral	United States of America	Health Care	Pharmaceuticals
PFIZER INC.	3.68%	B+	Neutral	United States of America	Health Care	Pharmaceuticals
GE HEALTHCARE TECHNOLOGIES INC.	3.61%	B+	Neutral	United States of America	Health Care	Health Care Equipment
JOHNSON & JOHNSON	3.54%	B+	Neutral	United States of America	Health Care	Pharmaceuticals
CVS HEALTH CORPORATION	3.44%	B+	Neutral	United States of America	Health Care	Health Care Services
ABBVIE INC.	3.31%	B+	Positive	United States of America	Health Care	Biotechnology
MOLINA HEALTHCARE, INC.	3.19%	A	Neutral	United States of America	Health Care	Managed Health Care
BRISTOL-MYERS SQUIBB CO	3.13%	B+	Neutral	United States of America	Health Care	Pharmaceuticals
NOVO NORDISK A/S	3.08%	A+	Neutral	Denmark	Health Care	Pharmaceuticals
HUMANA INC.	3.00%	A	Positive	United States of America	Health Care	Managed Health Care
ROCHE HOLDING AG	2.98%	B+	Neutral	Switzerland	Health Care	Pharmaceuticals
THE CIGNA GROUP	2.97%	A	Neutral	United States of America	Health Care	Health Care Services
CENTENE CORPORATION	2.96%	А	Neutral	United States of America	Health Care	Managed Health Care

Controversy Analysis

The analysis is carried out only on the corporate component of the portfolio

